Скачать с ютуб Assessing the ARANOTE Trial: Role of Darolutamide in Enhancing ADT for HSPC в хорошем качестве

Assessing the ARANOTE Trial: Role of Darolutamide in Enhancing ADT for HSPC

A roundtable discussion, moderated by Andrew Lacetti, MD, MS, of Memorial Sloan Kettering Cancer Center, focused on the treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC), including insights on the integration of recent research and clinical trials, how molecular subtyping affects treatment decisions, the future of care, and more. Dr. Lacetti was joined by Eleni Efstathiou, MD, PhD, of Houston Methodist Cancer Center; Ulka Vaishampayan, MD, of University of Micihgan; and Michael Schweizer, MD, of Red Hutchinson Cancer Center. In the third part of this roundtable series, the panelists share their thoughts on the results of the ARANOTE trial and androgen deprivation therapy approaches to HSPC.